Tesamorelin is a synthetic, stabilized analog of growth-hormone-releasing hormone (GHRH) that signals your own pituitary to release growth hormone — and, unlike most such peptides, it has FDA-approved human data showing it selectively reduces visceral abdominal fat. It is approved under the brand Egrifta specifically for adults with HIV-associated lipodystrophy, where deep abdominal fat accumulates as a side effect of the condition and its treatment.
That specificity matters, and most of the marketing around tesamorelin erases it. What follows is a plain-language read on the biology, the actual trial evidence, and where the honest boundaries of that evidence sit.
What is tesamorelin?
Tesamorelin is a 44-amino-acid peptide based on human growth-hormone-releasing hormone, modified with a hexenoyl group at one end to slow its breakdown and extend its activity (EGRIFTA prescribing information, FDA). Like sermorelin, it is a secretagogue — it does not contain growth hormone. It prompts the pituitary to make and release the body’s own growth hormone on the body’s own schedule.
The practical difference from sermorelin is longevity and evidence: tesamorelin is a longer-acting molecule that carried a full FDA drug-development program, so its effects on body fat are documented in large human trials rather than inferred.
How does tesamorelin work?
Tesamorelin binds GHRH receptors on the pituitary and stimulates pulsatile growth-hormone secretion, which raises insulin-like growth factor 1 (IGF-1), the downstream signal of growth-hormone activity (FDA label). Elevated growth-hormone signaling shifts fat metabolism, and the tissue most sensitive to that shift is visceral adipose tissue — the metabolically active fat packed around the abdominal organs.
Because it works upstream through the pituitary, tesamorelin preserves the body’s pulsatile release rather than flooding the system with outside growth hormone. That is the same design logic behind the whole GHRH-analog class.
What does the evidence show for visceral fat?
This is where tesamorelin stands apart. In the pivotal randomized trial of 412 adults with HIV and abdominal fat accumulation, tesamorelin reduced visceral adipose tissue by about 15% over 26 weeks, while the placebo group’s visceral fat rose slightly (Falutz et al., N Engl J Med 2007;357:2359). Pooled Phase III data showed a roughly 15.4% reduction versus placebo (FDA summary review).
Two details make the finding notable. First, the effect was selective — it concentrated on visceral fat and barely changed the fat under the skin, which is unusual. Second, it came with lower triglycerides. IGF-1 rose substantially, consistent with the mechanism.
Does tesamorelin affect liver fat?
Yes, in the same HIV population. A randomized trial found tesamorelin reduced liver fat and limited progression of fibrosis over a year, alongside a visceral-fat reduction of about 10% versus a rise on placebo (Stanley et al., JAMA 2014). This is biologically important because visceral and liver fat travel together, but it is still evidence generated in people with HIV — not a general fatty-liver indication.
Is tesamorelin FDA-approved, and who is it for?
Tesamorelin was FDA-approved in 2010 (as Egrifta, later reformulated) to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, and it remains the only approved therapy for that specific use (FDA label). It is not approved for general obesity, cosmetic fat reduction, or athletic use.
Outside HIV lipodystrophy, tesamorelin is prescribed off-label, often as a compounded medication. The mechanism is sound and the visceral-fat data are real, but the controlled human outcome evidence lives in the HIV population, and that boundary should always be visible to the patient.
What are the limits and risks?
Three honest caveats. First, the effect is reversible: visceral fat returns toward baseline within roughly six months of stopping, so tesamorelin is a maintained protocol, not a one-time correction. Second, it raises IGF-1, and because the long-term effect of sustained IGF-1 elevation on tumor growth is not fully known, it is contraindicated in active malignancy and IGF-1 should be monitored (FDA label). Third, growth-hormone signaling can raise blood sugar, so glucose is watched, particularly in people with insulin resistance or diabetes. It is also contraindicated in pregnancy and in people with an active disruption of the pituitary axis.
How Trellis approaches tesamorelin
Trellis Vitality is the accessibly-priced, patient-first alternative to premium-gated longevity clinics — on-demand and at home, without a five-figure annual membership. Where tesamorelin fits a patient, it is prescribed through a licensed clinical flow and, for non-HIV use, dispensed as a compounded medication with the off-label status stated plainly.
Every protocol begins with a free Vitality Lab Kit and baseline labs — including IGF-1 and metabolic markers — so the decision to start and to continue is anchored to your own numbers, not a before-and-after photo. If your real target is deep abdominal fat, it is worth reading how tesamorelin sits alongside GLP-1 medications in peptides for visceral fat and GLP-1 weight loss.
Tesamorelin is FDA-approved only for HIV-associated lipodystrophy; other uses are off-label. For non-HIV use it is prescribed and compounded by a state-licensed, FDA-regulated compounding pharmacy. Compounded medications are not FDA-approved as finished products, and nothing here is a promise of results or a treatment for any disease. Use is decided within a licensed clinical relationship.
Tesamorelin FAQ
What is tesamorelin used for? Tesamorelin is FDA-approved to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. Any other use — including general visceral-fat reduction — is off-label.
How is tesamorelin different from sermorelin? Both are GHRH analogs that prompt your own pituitary to release growth hormone. Tesamorelin is a longer-acting, stabilized molecule with FDA-approved human data specifically showing selective visceral-fat reduction; sermorelin is a shorter GHRH (1-29) fragment used more broadly for growth-hormone-axis support.
Does tesamorelin work for general weight loss? No. Tesamorelin selectively lowers visceral (deep abdominal) fat and barely changes fat under the skin or total body weight. It is not approved or evidenced as a general weight-loss drug.
Is tesamorelin’s effect permanent? No. The effect depends on continued use — visceral fat returns toward baseline within about six months of stopping, so it is a maintained protocol rather than a one-time fix.
Is tesamorelin safe? In trials it was generally tolerated, but it raises IGF-1 and can affect blood sugar, so it needs clinician supervision and IGF-1 monitoring. It is contraindicated in active malignancy, pregnancy, and disruption of the pituitary axis.
The measured way to decide is to look at your own numbers first. Begin your assessment →
Sources
- EGRIFTA (tesamorelin for injection) prescribing information. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022505Orig1s010lbl.pdf
- FDA Summary Review, NDA 022505 (tesamorelin). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022505Orig1s000SumR.pdf
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359–2370. https://www.nejm.org/doi/full/10.1056/NEJMoa072375
- Stanley TL, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380–389. https://jamanetwork.com/journals/jama/fullarticle/1889139